Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
Adi DiabScott S TykodiGregory A DanielsMichele MaioBrendan D CurtiKarl D LewisSekwon JangEwa Anna KalinkaIgor PuzanovAlexander I SpiraDaniel C ChoShanhong GuanErika G PuenteTuan NguyenUte HochSue L CurrieWei LinMary A TagliaferriJonathan ZalevskyMario SznolMichael E HurwitzPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
BEMPEG in combination with NIVO was tolerated, with relatively low rates of grade 3 and 4 treatment-related and immune-mediated adverse events. The combination had encouraging antitumor activity in first-line metastatic melanoma, including an extended median progression-free survival. Exploratory analyses associated noninvasive, on-treatment biomarkers with response, before radiologic evidence was observed.
Keyphrases